• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biofrontera Inc.

    11/4/22 4:05:25 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRI alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Biofrontera Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    09077D 100

    (CUSIP Number)

     

    October 25, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No. 09077D 10013GPage 2 of 6 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Abshagen Consulting GmbH

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

    SOLE VOTING POWER

     

    3,148,042

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    3,148,042

      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,148,042

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    11.8% (See Note 1)

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

     

       

    Note 1: The denominator for this calculation is based on 26,699,002 shares of Biofrontera Inc. common stock outstanding as of the date of this Schedule 13G, based on (i) the 3,148,042 shares issued to the Reporting Person, as reported in Biofrontera Inc.’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “Commission”) on October 31, 2022 plus (ii) 23,550,960 shares of Biofrontera Inc. common stock outstanding as reported in Biofrontera Inc.’s most recent Quarterly Report on Form 10-Q filed with the Commission on August 12, 2022.

     

     
    CUSIP No. 09077D 10013GPage 3 of 6 Pages

     

    Item 1.

     

      (a)

    Name of Issuer

     

    Biofrontera Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

    120 Presidential Way, Suite 330
    Woburn, MA 01801

     

    Item 2.

     

      (a)

    Name of Person Filing

     

    Abshagen Consulting GmbH

         
      (b)

    Address of the Principal Office or, if none, residence

     

    Burgunderweg 8

    Weinheim 69469 Germany

         
      (c)

    Citizenship

     

    Germany

         
      (d)

    Title of Class of Securities

     

    Common Stock, par value $0.001 per share

         
      (e)

    CUSIP Number

     

    09077D 100

     

     
    CUSIP No. 09077D 10013GPage 4 of 6 Pages

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

      (a)   Amount beneficially owned:
    3,148,042 shares of Biofrontera Inc.’s common stock
             
      (b)   Percent of class:
    11.8%. The percent of class is based on a denominator for this calculation of 26,699,002 shares of Biofrontera Inc. common stock outstanding, which is derived from (i) the 3,148,042 shares issued to the Reporting Person, as reported in Biofrontera Inc.’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “Commission”) on October 31, 2022 plus (ii) 23,550,960 shares of Biofrontera Inc. common stock outstanding as reported in Biofrontera Inc.’s most recent Quarterly Report on Form 10-Q filed with the Commission on August 12, 2022.
             
      (c)   Number of shares as to which the person has:
             
          (i)

    Sole power to vote or to direct the vote .

    3,148,042

             
          (ii)

    Shared power to vote or to direct the vote .

    0

             
          (iii)

    Sole power to dispose or to direct the disposition of .

    3,148,042

             
          (iv)

    Shared power to dispose or to direct the disposition of .

    0

     

     
    CUSIP No. 09077D 10013GPage 5 of 6 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

     
    CUSIP No. 09077D 10013GPage 6 of 6 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 4, 2022

     

      ABSHAGEN CONSULTING GMBH
       
      By: /s/ Ulrich Abshagen
      Name: Ulrich Abshagen
      Title: Owner and Managing Director

     

     

     

    Get the next $BFRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRI

    DatePrice TargetRatingAnalyst
    12/15/2021$11.00Buy
    Benchmark
    11/24/2021$20.00Buy
    Roth Capital
    More analyst ratings

    $BFRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Link Christian Alexander Ansgar

    3 - Biofrontera Inc. (0001858685) (Issuer)

    9/30/25 8:53:07 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Vv Beteiligungen Aktiengesellschaft claimed ownership of 458,884 shares (SEC Form 3)

    3 - Biofrontera Inc. (0001858685) (Issuer)

    9/30/25 8:47:57 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Delphi Unternehmensberatung Aktiengesellschaft claimed ownership of 458,884 shares (SEC Form 3)

    3 - Biofrontera Inc. (0001858685) (Issuer)

    9/30/25 8:42:21 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

    Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p<0.0003)Actinic keratosis (AK) is the most common skin condition diagnosed by US dermatologists1If left untreated, AK may progress to squamous cell carcinoma2,3 WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz® PDT with the red-light LED (RhodoLED®) platform for the tre

    2/9/26 9:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

    Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2

    1/13/26 8:30:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

    Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne are the two most commonly diagnosed skin disorders in the US1 WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database lock of two clinical studies evaluating Ameluz® PDT, marking an important milestone ahead of several anticipated data and regulatory events in 2026. The databases for th

    1/8/26 8:45:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    SEC Filings

    View All

    Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    2/9/26 9:20:43 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.

    SCHEDULE 13G/A - Biofrontera Inc. (0001858685) (Subject)

    1/28/26 2:10:17 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    1/13/26 8:35:24 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Benchmark initiated coverage on Biofrontera with a new price target

    Benchmark initiated coverage of Biofrontera with a rating of Buy and set a new price target of $11.00

    12/15/21 6:49:18 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Biofrontera with a new price target

    Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00

    11/24/21 8:02:09 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Leadership Updates

    Live Leadership Updates

    View All

    Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

    Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthening of the Company's management follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz® and RhodoLED® for the US market, including the FDA approval and al

    8/11/25 4:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

    WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over

    8/29/23 8:00:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

    WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o

    7/12/23 8:00:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 3:54:03 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 1:13:39 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/13/24 2:12:35 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

    Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2

    1/13/26 8:30:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and nine months ended September 30, 2025 and provided a business update. Financial highlights Revenues for the first nine months of 2025 were stable with $24.6 million compared to $24.8 million for the same period in 2024The 2025 result was achieved without the buy-in effects from a price increaseIn 3Q25 revenues were $7.0 million, lagging behind the

    11/13/25 8:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

    WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference CallDate:Thursday,

    11/6/25 4:01:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care